Literature DB >> 26036228

Preoperative INR and postoperative major bleeding and mortality: A retrospective cohort study.

Hani Tamim1,2, Mohamad Habbal3, Antoine Saliba4, Khaled Musallam5, Muhyeddine Al-Taki6, Jamal Hoballah7, Sarah Jamali8, Ali Taher9.   

Abstract

Little research has been done on the current cut-off international normalized ratio (INR) value of 1.5 for patients undergoing surgery. The objectives of this study are to assess the association between INR and postoperative major bleeding and mortality in patients undergoing surgery and to identify an ideal pre-operative INR for surgical patients. We analyzed data from the American College of Surgeons' National Surgical Quality Improvement Program database between 2008 and 2011 (636,231 patients). The primary outcomes were major bleeding and mortality at 30 days postoperatively. Multivariate logistic regression analyses were carried out to assess these associations. Compared to an INR of <1, the adjusted odds ratio (aOR) for major bleeding was 1.22 (95 % CI 1.18-1.25) for INR 1-1.49, 1.48 (95 % CI 1.40-1.56) for INR 1.5-1.9, and 1.49 (95 % CI 1.39-1.60) for INR ≥2. The aOR for mortality at 30 days post-operation compared to INR of <1 was 1.51 (95 % CI 1.41-1.62), 2.31 (95 % CI 2.12-2.52), and 2.81 (95 % CI 2.56-3.10) for INR 1-1.49, 1.5-1.9, and ≥2, respectively. The ideal pre-operative INR value to predict an increased risk for major bleeding was 1.10 and 1.13 for mortality. In conclusion, preoperative INR is significantly and independently associated with postoperative major bleeding and mortality.

Entities:  

Keywords:  ACS NSQIP; Hemostasis; INR; Outcomes; Prothrombin time; Surgery

Mesh:

Year:  2016        PMID: 26036228     DOI: 10.1007/s11239-015-1235-1

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  22 in total

Review 1.  Factor VII Deficiency.

Authors:  David J Perry
Journal:  Br J Haematol       Date:  2002-09       Impact factor: 6.998

2.  Vitamin K intake, body mass index and warfarin maintenance dose.

Authors:  Edmond K Kabagambe; T Mark Beasley; Nita A Limdi
Journal:  Cardiology       Date:  2013-09-19       Impact factor: 1.869

3.  Use and utility of preoperative hemostatic screening and patient history in adult neurosurgical patients.

Authors:  Andreea Seicean; Nicholas K Schiltz; Sinziana Seicean; Nima Alan; Duncan Neuhauser; Robert J Weil
Journal:  J Neurosurg       Date:  2012-02-17       Impact factor: 5.115

4.  Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.

Authors:  P Petersen; G Boysen; J Godtfredsen; E D Andersen; B Andersen
Journal:  Lancet       Date:  1989-01-28       Impact factor: 79.321

Review 5.  Surgery in the patient with liver disease.

Authors:  Lawrence S Friedman
Journal:  Trans Am Clin Climatol Assoc       Date:  2010

Review 6.  Management of surgical patients receiving anticoagulation and antiplatelet agents.

Authors:  J Thachil; A Gatt; V Martlew
Journal:  Br J Surg       Date:  2008-12       Impact factor: 6.939

7.  Time for changing coagulation management in trauma-related massive bleeding.

Authors:  Dietmar Fries; Petra Innerhofer; Wolfgang Schobersberger
Journal:  Curr Opin Anaesthesiol       Date:  2009-04       Impact factor: 2.706

Review 8.  Venous thromboembolism: epidemiology and magnitude of the problem.

Authors:  Samuel Z Goldhaber
Journal:  Best Pract Res Clin Haematol       Date:  2012-08-09       Impact factor: 3.020

9.  The patient safety in surgery study: background, study design, and patient populations.

Authors:  Shukri F Khuri; William G Henderson; Jennifer Daley; Olga Jonasson; R Scott Jones; Darrell A Campbell; Aaron S Fink; Robert M Mentzer; Janet E Steeger
Journal:  J Am Coll Surg       Date:  2007-06       Impact factor: 6.113

10.  Statistics review 13: receiver operating characteristic curves.

Authors:  Viv Bewick; Liz Cheek; Jonathan Ball
Journal:  Crit Care       Date:  2004-11-04       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.